September 2017 in “Journal of Investigative Dermatology Symposium Proceedings”
Prostaglandin D2 increases testosterone production in skin cells through a process involving reactive oxygen species, which could be a new target for treating hair loss and other skin conditions driven by testosterone.
1 citations,
April 2016 in “Journal of Investigative Dermatology”
Prostaglandin D2 increases testosterone levels in skin cells through reactive oxygen species, not enzymes, which could lead to new hair loss treatments.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.
Poor diet and lifestyle contribute to male pattern baldness. Treatments like Minoxidil, dietary changes, and lifestyle adjustments may help slow hair loss.
Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.